Impact of an Antimicrobial Stewardship Program on the Incidence of Carbapenem Resistant Gram-Negative Bacilli: An Interrupted Time-Series Analysis
Teresa López-Viñau,
Germán Peñalva,
Lucrecia García-Martínez,
Juan José Castón,
Montserrat Muñoz-Rosa,
Ángela Cano,
Manuel Recio,
José Miguel Cisneros,
Elena Pérez-Nadales,
José Rumbao Aguirre,
Elena García-Martínez,
Inmaculada Salcedo,
José Ramón del Prado,
Carmen de la Fuente,
Luis Martínez-Martínez,
Irene Gracia-Ahufinger,
Julián Torre-Cisneros
Affiliations
Teresa López-Viñau
Pharmacy Unit, Reina Sofia University Hospital, 14004 Cordoba, Spain
Germán Peñalva
Department of Infectious Diseases, Microbiology and Preventive Medicine, Institute of Biomedicine of Seville, Virgen del Rocio University Hospital, 41013 Seville, Spain
Lucrecia García-Martínez
Pharmacy Unit, Reina Sofia University Hospital, 14004 Cordoba, Spain
Juan José Castón
Infectious Diseases Unit, Reina Sofia University Hospital, Maimonides, Biomedical Research Institute of Cordoba (IMIBIC), University of Cordoba (UCO), 14004 Cordoba, Spain
Montserrat Muñoz-Rosa
Microbiology Unit, Reina Sofia University Hospital, IMIBIC, Department of Agricultural Chemistry, Edafology and Microbiology, University of Cordoba, 14004 Cordoba, Spain
Ángela Cano
Infectious Diseases Unit, Reina Sofia University Hospital, Maimonides, Biomedical Research Institute of Cordoba (IMIBIC), University of Cordoba (UCO), 14004 Cordoba, Spain
Manuel Recio
Infectious Diseases Unit, Reina Sofia University Hospital, Maimonides, Biomedical Research Institute of Cordoba (IMIBIC), University of Cordoba (UCO), 14004 Cordoba, Spain
José Miguel Cisneros
Department of Infectious Diseases, Microbiology and Preventive Medicine, Institute of Biomedicine of Seville, Virgen del Rocio University Hospital, 41013 Seville, Spain
Elena Pérez-Nadales
Infectious Diseases Unit, Reina Sofia University Hospital, Maimonides, Biomedical Research Institute of Cordoba (IMIBIC), University of Cordoba (UCO), 14004 Cordoba, Spain
José Rumbao Aguirre
Hospital Management, Reina Sofia University Hospital, 14004 Cordoba, Spain
Elena García-Martínez
Hospital Management, Reina Sofia University Hospital, 14004 Cordoba, Spain
Inmaculada Salcedo
Preventive Medicine Unit, Reina Sofia University Hospital, 14004 Cordoba, Spain
José Ramón del Prado
Pharmacy Unit, Reina Sofia University Hospital, 14004 Cordoba, Spain
Carmen de la Fuente
Intensive Care Unit, Reina Sofia University Hospital, 14004 Cordoba, Spain
Luis Martínez-Martínez
Microbiology Unit, Reina Sofia University Hospital, IMIBIC, Department of Agricultural Chemistry, Edafology and Microbiology, University of Cordoba, 14004 Cordoba, Spain
Irene Gracia-Ahufinger
Microbiology Unit, Reina Sofia University Hospital, IMIBIC, Department of Agricultural Chemistry, Edafology and Microbiology, University of Cordoba, 14004 Cordoba, Spain
Julián Torre-Cisneros
Infectious Diseases Unit, Reina Sofia University Hospital, Maimonides, Biomedical Research Institute of Cordoba (IMIBIC), University of Cordoba (UCO), 14004 Cordoba, Spain
Carbapenem-resistant Gram-negative bacilli (CR-GNB) are a critical public health threat, and carbapenem use contributes to their spread. Antimicrobial stewardship programs (ASPs) have proven successful in reducing antimicrobial use. However, evidence on the impact of carbapenem resistance remains unclear. We evaluated the impact of a multifaceted ASP on carbapenem use and incidence of CR-GNB in a high-endemic hospital. An interrupted time-series analysis was conducted one year before and two years after starting the ASP to assess carbapenem consumption, CR-GNB incidence, death rates of sentinel events, and other variables potentially related to CR-GNB incidence. An intense reduction in carbapenem consumption occurred after starting the intervention and was sustained two years later (relative effect −83.51%; 95% CI −87.23 to −79.79). The incidence density of CR-GNB decreased by −0.915 cases per 1000 occupied bed days (95% CI −1.743 to −0.087). This effect was especially marked in CR-Klebsiella pneumoniae and CR-Escherichia coli, reversing the pre-intervention upward trend and leading to a relative reduction of −91.15% (95% CI −105.53 to −76.76) and −89.93% (95% CI −107.03 to −72.83), respectively, two years after starting the program. Death rates did not change. This ASP contributed to decreasing CR-GNB incidence through a sustained reduction in antibiotic use without increasing mortality rates.